Articles from Teleflex Incorporated

Including market leading Arrow™ CVCs and Arterial Catheters

WAYNE, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSETFX), is scheduled to speak at the 43rd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis in San Francisco, California, on Tuesday, January 14, 2025, at 5:15 p.m. (PT).

WAYNE, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSETFX), is scheduled to speak at the 36th Annual Piper Sandler Healthcare Conference at The Lotte New York Palace, New York, NY, on Tuesday, December 3, 2024, at 9:30 a.m. (ET).

WAYNE, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSETFX), is scheduled to speak at the Jefferies London Healthcare Conference, on Thursday, November 21, 2024, at 9:30 a.m. (GMT).

WAYNE, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable December 16, 2024, to shareholders of record at the close of business on November 15, 2024.

WAYNE, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) (the “Company”) today announced financial results for the third quarter ended September 29, 2024.

Randomized, controlled study will be first in personalized spacing evidence to include patients who have a prostate cancer recurrence after prostatectomy.

•   Barrigel™ rectal spacer provides high quality rectal spacing, enabling low dose to the rectum during prostate cancer radiation therapy, with an excellent toxicity and safety profile; and low incidence (0.32-1%) of rectal wall infiltration (RWI), which can be safely reversed using hyaluronidase4,5

WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, October 31, 2024.

• Highlights include new safety and efficacy data of Barrigel™ rectal spacer, the first and only sculptable rectal spacer1-3

WAYNE, Pa., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSETFX), is scheduled to speak at the Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York, on Friday, September 6, 2024, at 7:45 a.m. (ET).

WAYNE, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX), a leading global provider of medical technologies, today announced the publication of a new retrospective analysis of clinical data linking the Titan SGS™ Stapler with enhanced clinical outcomes and significant procedural efficiency benefits compared with multi-fire surgical staplers in patients undergoing laparoscopic sleeve gastrectomy (LSG).1 The study was conducted by five surgeons at a Corewell Health Hospital in Grand Rapids, MI, an MBSAQIP-accredited facility that is a Center of Excellence for bariatric surgery.* The study results appear in the current issue of Obesity Surgery.1

WAYNE, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 16, 2024, to shareholders of record at the close of business on August 15, 2024.

Announces $500 million share repurchase authorization inclusive of a $200 million accelerated share repurchase of common stock

This milestone highlights Teleflex’s commitment to providing interventionalists with new tools specifically engineered to address unmet clinical needs.

Hemostatic Dressings and Devices are Now Available at Special Pricing for Premier Members

WAYNE, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX), a leading global provider of medical technologies, today announced the establishment of the Teleflex Center for Antimicrobial Protection (TCAP) as a strategic branch of its Vascular Access business unit led by Chuck Gartner, Director of Marketing - Strategic Initiatives.

WAYNE, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 1, 2024.

Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program

The First and Only Sterile, Single-Use IO Tray Cleared by the U.S. Food and Drug Administration

WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 American Urological Association Annual Meeting in San Antonio, TX, May 3 – 6, 2024, showcasing excellent patient experience* with the Prostatic Urethral Lift (PUL) with the UroLift™ System for benign prostatic hyperplasia (BPH).

WAYNE, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 14, 2024, to shareholders of record at the close of business on May 15, 2024. Additional information about Teleflex can be obtained from the company’s website at teleflex.com.

WAYNE, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) (the “Company”) today announced financial results for the first quarter ended March 31, 2024.

WAYNE, Pa., May 01, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX), a global leader in medical technologies, today announced the presentation of multiple clinical studies at the 2024 American Urological Association Annual Meeting, which is being held in San Antonio, TX, from May 3 – 6, 2024. These studies add to the growing body of clinical evidence around the safety, efficacy and patient experience* with a Prostatic Urethral Lift (PUL) using the UroLift™ System for benign BPH.

Company expands structural heart portfolio and begins the limited market release of a bipolar temporary pacing guidewire intended to introduce and position catheters and other interventional devices within the chambers of the heart while transmitting an electrical signal from an external pulse generator to the heart

WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSETFX), is scheduled to speak at the BofA Securities 2024 Health Care Conference at the Encore Hotel in Las Vegas, Nevada, on Tuesday, May 14, 2024, at 2:20 p.m. (PT).

WAYNE, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 2, 2024.

WAYNE, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced Tissue Control (ATC) feature on its unified UroLift™ 2 System platform designed for the treatment of benign prostatic hyperplasia (BPH) symptoms in men with all prostate types up to 100g. The UroLift™ 2 System with Advanced Tissue Control (UroLift™ 2 ATC) has received FDA clearance, marking a significant advancement in BPH care.

Teleflex commits to reach net-zero greenhouse gas emissions across its value chain by 2050.

WAYNE, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable March 15, 2024, to shareholders of record at the close of business on March 1, 2024. Additional information about Teleflex can be obtained from the company’s website at teleflex.com.

WAYNE, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) (the “Company”) today announced financial results for the fourth quarter ended December 31, 2023.

WAYNE, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSETFX), is scheduled to speak at the 45th Annual Raymond James Institutional Investors Conference at the JW Marriott Orlando Grande Lakes, Orlando, FL, on Tuesday, March 5, 2024, at 1:40 p.m. (ET).

WAYNE, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) will host a conference call to discuss its fourth quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 22, 2024.

A New Choice for Bariatric Surgeons: Titan SGS™ Standard Staple Line Reinforcement with GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement

WAYNE, Pa., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSETFX), is scheduled to speak at the 42nd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis in San Francisco, California, on Tuesday, January 9, 2024, at 3:00 p.m. (PT).

WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX), a leading global provider of medical technologies, today announced it was awarded the Peripheral Access purchasing agreement with Premier, Inc. Effective December 1st, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex’s Peripheral Access products. Premier has awarded Teleflex a national multi-source agreement for Peripherally Inserted Central Catheters (PICCs), PICC navigation equipment, and Midlines.

Registry Intends to Examine Contemporary On-Label Use of the MANTA™ Vascular Closure Device Including Appropriate Patient Selection and Proper Vascular Access

WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature journal Prostate Cancer and Prostatic Diseases reinforces the position of the UroLift™ System as the gold standard in minimally invasive surgical treatment (MIST) for benign prostatic hyperplasia (BPH), or enlarged prostate. Retreatment Rates and Postprocedural Complications Are Higher Than Expected After BPH Surgeries: A U.S. Healthcare Claims and Utilization Study is the largest longitudinal healthcare claims study evaluating complication and retreatment rates after BPH treatment with leading surgical and MIST ever conducted, and the only study to include all outpatient sites of service.1

WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSETFX), is scheduled to speak at the 35th Annual Piper Sandler Healthcare Conference at The Lotte New York Palace, New York, NY, on Tuesday, November 28, 2023 at 11:30 a.m. (ET).

WAYNE, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable December 15, 2023, to shareholders of record at the close of business on November 15, 2023.   Additional information about Teleflex can be obtained from the company’s website at teleflex.com.

WAYNE, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) (the “Company”) today announced financial results for the third quarter ended October 1, 2023.

WAYNE, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSETFX), is scheduled to speak at the Jefferies London Healthcare Conference, on Tuesday, November 14, 2023, at 9:00 a.m. (GMT).

WAYNE, Pa., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 2, 2023.

WAYNE, Pa., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of Palette Life Sciences AB. The acquisition adds Barrigel®, a biodegradable sculptable rectal spacer, to Teleflex’s Interventional Urology portfolio. Barrigel® is a Non-Animal Stabilized Hyaluronic Acid (NASHA) spacer designed to reduce radiation delivered to the rectum during prostate cancer radiation therapy, while increasing tumor control and patient quality of life.1 The Palette Life Sciences portfolio also includes Deflux® and Solesta®, which are NASHA based tissue bulking agents designed to treat pediatric vesicoureteral reflux and fecal incontinence, respectively.

WAYNE, Pa., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX), a leading global provider of medical technologies, today announced it has been selected to exhibit Arrow™ VPS Rhythm™ DLX Device and Arrow™ PICCs preloaded with the NaviCurve™ Stylet at the Vizient Innovative Technology Exchange. Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company, will hold the Exchange on Oct. 3 in Grapevine, Texas.

Men With Bothersome Urinary Symptoms Find Travel Less Enjoyable Due to Frequent Bathroom Needs

WAYNE, Pa., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSETFX), is scheduled to speak at the Morgan Stanley 21st Annual Global Healthcare Conference at the Sheraton New York, on Wednesday, September 13, 2023, at 11:30 a.m. (ET).

WAYNE, Pa., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX), a leading global provider of medical technologies, today announced the release of the Arrow™ ErgoPack™ Complete Kits with Hemodialysis and Large Bore catheters in the United States. This update is intended to streamline insertion workflow for clinicians and provide more options to suit their needs. Clinicians can choose between Arrowg+ard Blue™ Hemodialysis or Large Bore lines in this expanded kit configuration, with a variety of French sizes, lumens, and lengths.

WAYNE, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 15, 2023, to shareholders of record at the close of business on August 15, 2023.   Additional information about Teleflex can be obtained from the company’s website at teleflex.com.

WAYNE, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) (the “Company”) today announced financial results for the second quarter ended July 2, 2023.

WAYNE, Pa., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX), a leading global provider of medical technologies, today announced the U.S Food and Drug Administration (FDA) has cleared the QuikClot Control+™ Hemostatic Device to include mild and moderate bleeding in cardiac surgical procedures and bone surface bleeding following a sternotomy. This allows clinicians to use the QuikClot Control+™ Device to control all bleeding in cardiac surgical procedures.

Acquisition will add Barrigel®, a biodegradable sculptable rectal spacer, to Teleflex’s Interventional Urology portfolio

WAYNE, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX), a leading global provider of medical technologies, today announced it was awarded three group purchasing agreements with Premier, Inc. Effective August 1st, 2023, the new agreements allow Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for select Teleflex products in the Laryngoscope Systems, Laryngeal Masks Airways, and Disposable Anesthesia Products categories.

WAYNE, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 3, 2023.

Enrollment Complete in Study Evaluating the Performance of the Ringer™ Perfusion Balloon Catheter in Patients Undergoing Percutaneous Coronary Interventions

WAYNE, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX), a leading global provider of medical technologies for critical care and surgery, has announced a global recall of affected batches of the below-mentioned Rüsch Endotracheal Tube products. The Rüsch Endotracheal Tube devices are indicated for oral or nasal intubation for airway management via insertion into a patient’s tracheal via nose or mouth. Stylets are used to aid insertion of endotracheal tubes into the trachea.

WAYNE, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX), a leading global provider of medical technologies, today announced a partnership with Shenzhen Insighters Medical Technology Co., Ltd. as the exclusive U.S. distributor of the Insighters® Video Laryngoscope system, which is designed to inspect the upper glottic airway and facilitate endotracheal intubation.

Company expands Structural Heart Portfolio with the first commercially available bipolar temporary pacing guidewire designed specifically for use during transcatheter aortic valve replacement (TAVR) and balloon aortic valvuloplasty (BAV)

First and Only IO Needle with MR Conditional Safety Status Labeling

WAYNE, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX), a leading global provider of medical technologies, today announced it was awarded two group purchasing agreements with Premier, Inc. Effective July 1st, 2023, the new agreements allow Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex’s Central Venous and Arterial Vascular Access products. Premier has awarded Teleflex a national agreement for Hemodynamic Monitoring Products and Accessories, a national agreement for Central Venous Access, a Sole Source for AscenDrive Central Venous Access, and a Sole Source for SURPASS Central Venous Access.

Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program

WAYNE, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 15, 2023, to shareholders of record at the close of business on May 15, 2023.   Additional information about Teleflex can be obtained from the company’s website at teleflex.com.

WAYNE, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) (the “Company”) today announced financial results for the first quarter ended April 2, 2023.

Research Presented at the American Urological Association Annual Meeting Confirms Five-Year Durability of UroLift® System and Highlights Low Rates of Procedural Complications

WAYNE, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX), a leading global provider of medical technologies, today announced the launch of two new devices designed to enhance PICC insertion procedures and reduce the chance of complications. The new Arrow® VPS Rhythm® DLX Device and NaviCurve™ Stylet are engineered to work together to give Vascular Access Specialists more efficient and predictable PICC placement.

WAYNE, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSETFX), is scheduled to speak at the Bank of America Securities 2023 Health Care Conference at the Encore Hotel in Las Vegas, Nevada, on Tuesday, May 9, 2023, at 10:00 a.m. (PT).

WAYNE, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 4, 2023.

Product Pairing Offers an Impactful Partnership for Bariatric Surgery

Presentations at the 38th Annual European Association of Urology Congress Reinforce Low Surgical Retreatment of the UroLift® System

WAYNE, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated (NYSETFX), is scheduled to speak at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, at 12:00 p.m. (ET).

WAYNE, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable March 15, 2023, to shareholders of record at the close of business on March 3, 2023. Additional information about Teleflex can be obtained from the company’s website at teleflex.com.

WAYNE, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) (the “Company”) today announced financial results for the fourth quarter ended December 31, 2022.

Triumph™ Catheter and GuideLiner® Coast™ Catheter to be featured at the CTO Plus Conference, February 23-24 in New York, NY

WAYNE, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSETFX), is scheduled to speak at the 44th Annual Raymond James Institutional Investors Conference at the JW Marriott Orlando Grande Lakes, Orlando, FL, on Tuesday, March 7, 2023, at 1:40 p.m. (ET).

WAYNE, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSETFX) will host a conference call to discuss its fourth quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 23, 2023.